ACTU Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.9M
-14.0%
5.7M
+21.7%
4.7M
-14.3%
5.5M
-8.3%
6.0M
R&D
2.1M
-19.4%
2.6M
+20.5%
2.1M
-2.2%
2.2M
-21.2%
2.8M
SG&A
2.8M
-9.6%
3.1M
+22.7%
2.6M
-22.3%
3.3M
+2.8%
3.2M
Operating Income
-4906588
+14.0%
-5705956
-21.7%
-4688473
+14.3%
-5472378
+8.3%
-5968877
EBITDA
-4906588
+14.0%
-5705956
-21.7%
-4688473
+14.3%
-5472378
+8.3%
-5968877
Net Income
-4866635
+13.5%
-5625749
-23.5%
-4553953
+15.8%
-5407470
+9.1%
-5949405
EPS (Basic)
$-0.20
+16.7%
$-0.24
-26.3%
$-0.19
+24.0%
$-0.25
+16.7%
$-0.30
EPS (Diluted)
$-0.20
+16.7%
$-0.24
-26.3%
$-0.19
+24.0%
$-0.25
+16.7%
$-0.30
Shares (Diluted)
23.9M
+1.4%
23.5M
-0.0%
23.5M
+10.1%
21.4M
+8.9%
19.6M
Actuate Therapeutics (ACTU) โ€” Financials